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Transmembrane protein 140 (TMEM140)
a b s t r a c t
During HSV-1 infection, the viral UL31 protein forms a complex with the UL34 protein at the cellular
nuclear membrane, where both proteins play important roles in the envelopment of viral nucleocapsids
and their egress into the cytoplasm. To characterize the mechanism of HSV-1 nucleocapsid egress, we
screened host proteins to identify proteins that interacted with UL31 via yeast two-hybrid analysis.
Transmembrane protein 140 (TMEM140), was identiﬁed and conﬁrmed to bind to and co-localize with
UL31 during viral infection. Further studies indicated that TMEM140 inhibits HSV-1 proliferation
through selectively blocking viral nucleocapsid egress during the viral assembly process. The blockage
function of TMEM140 is mediated by impeding the formation of the UL31–UL34 complex due to
competitive binding to UL31. Collectively, these data suggest the essentiality of the UL31–UL34
interaction in the viral nucleocapsid egress process and provide a new anti-HSV-1 strategy in viral
assembly process of nucleocapsid egress.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Herpes simplex virus 1 (HSV-1) is a double-stranded DNA virus
consisting of a viral DNA genome that is surrounded by a capsid
and an envelope that is associated with tegument proteins. The
HSV-1 infectious cycle consists of viral component synthesis, that
begins with viral genome DNA replication and nucleocapsid
assembly in the nucleus. Nucleocapsid assembly is followed by
nuclear egress, cytoplasmic capsids then bud into TGN-derived
vesicles, where they acquire most of the tegument and envelopes,
and the progeny is ultimately released from the infected cells. The
production of mature, infective virions requires the step-by-step
incorporation of every viral component. Each process involves
complicated and precise interactions between viral components
and cellular molecules. Viral replication is promoted by virus-
encoded proteins that alter cellular structures and metabolism,
whereas host cells have developed mechanisms for protection
against viral replication through evolution (Roizman and Taddeo,
2007).
HSV-1 nucleocapsids are assembled in the nuclei of infected
cells and acquire a primary envelope by budding through the inner
nuclear membrane into the perinuclear space after the viral DNA
genome is encapsidated (Mettenleiter, 2002; Johnson and Baines,
2011). Two conserved viral proteins, which are encoded by the
UL31 and UL34 genes, are involved in this biological event, during
which they form a complex termed the nuclear egress complex
(NEC). The absence of either molecule prevents HSV-1 nucleocap-
sid egress from the nucleus (Chang et al., 1997; Roller et al., 2000;
Reynolds et al., 2001). The UL31 protein has been shown to be a
phosphoprotein that is recruited to the nuclear membrane by
UL34, which is an integral membrane protein with an N-terminal
nucleoplasmic domain and a C-terminal transmembrane domain,
to form a complex that co-localizes at the nuclear rim of infected
cells (Yamauchi et al., 2001; Zhu et al., 1999; Ye and Roizman,
2000). It has been reported that the interaction between UL31 and
UL34 at the nuclear rim and likely, in the nucleoplasm are required
for viral nucleocapsid egress from the nucleus during primary
envelopment (Reynolds et al., 2001; Zhu et al., 1999; Reynolds et
al., 2002; Fuchs et al., 2002; Chang and Roizman, 1993; Kato et al.,
2006). By associating with the nucleus and the nuclear lamina
network, the UL31–UL34 complex is presumed to alter the
nucleus, and nuclear membrane structures and the constructed
nucleocapsids subsequently migrate to the inner nuclear mem-
brane for egress and primary envelopment (Reynolds et al., 2004;
Simpson-Holley et al., 2004; Simpson-Holley et al., 2005). In
addition to the UL31–UL34 complex, the viral protein kinases
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UL13 and US3 as well as cellular protein kinase C (PKC) in the NEC
are recruited for viral nucleocapsid egress and envelopment
(Reynolds et al., 2002; Kato et al., 2006; Ryckman and Roller,
2004; Mou et al., 2009; Leach and Roller, 2010). These actions
suggest that the UL31–UL34 complex likely interacts with the
associated host-cell proteins in the process of facilitating viral
nucleocapsid egress.
To investigate the details of the mechanism of HSV-1 nucleo-
capsid egress from the nucleus and of the interaction between
the UL31 and UL34 complex and the host cell during viral egress
and primary envelopment, we screened host proteins to identify
proteins that are capable of interacting with UL31 in cells using
yeast two-hybrid analysis. Transmembrane protein 140 (TMEM140),
which has an unknown function, was identiﬁed and conﬁrmed to
interact and co-localize with UL31 in the nucleus upon transfection
with UL31 or viral infection. Subsequent studies demonstrated that
TMEM140 inhibits HSV-1 proliferation after its over-expression by
selectively impeding viral nucleocapsid egress from the nucleus
rather than by being exploited by the virion. This inhibitory
function is achieved by inhibiting the formation of the UL31–UL34
complex due to the competitive binding of TMEM140 to UL31. This
ﬁnding demonstrates that the interaction between UL31 and UL34
is essential for viral nucleocapsid egress and that inhibition of the
formation of the UL31–UL34 nuclear egress complex by the
competitive binding of TMEM140 leads to reduced virion egress,
which inhibits viral proliferation. This observation provides new
directions for anti-HSV-1 strategies through impeding viral nucleo-
capsid egress.
Results
Identiﬁcation of TMEM140 as a protein that interacts with UL31
A yeast two-hybrid screen of the cellular proteins encoded by a
cDNA library of human liver tissue was used to identify proteins
that interact with the UL31 protein. This assay showed that several
host cellular proteins could equally interact with UL31 (Table S1).
Based on the demonstration in the literature that UL31 is localized
to the nuclear membrane, the potential interactions between three
membrane protein molecules, transmembrane 140, transmem-
brane protein 176 and lysosomal-associated membrane protein 3,
and UL31 were further screened in transfected yeast cells. The
results revealed an even more clear interaction between TMEM140
and UL31 in yeast cells than what was conﬁrmed using β-gal
activity detection (Fig. 1a). Based on these data, the interaction
between TMEM140 and UL31 was further assayed using immuno-
precipitation in Vero cells. Using an anti-TMEM140 antibody,
TMEM140 was detected in the complex that was precipitated by
the anti-UL31 antibody using immunoblotting of cells transfected
with the TMEM140 and UL31 genes and cells infected with HSV-1
(Fig. 1b). As a gene founded by DNA sequence and annotated in
2003, all we know about TMEM140 is that it is located on human
chromosome 7 and predicted to have 4 potential transmembrane
domains by bioinformatics analysis (Scherer et al., 2003; Ota et al.,
2004). Thus, we performed ﬂuorescence detection for the cellular
localization of TMEM140 using an expression plasmid containing
a fused EGFP-TMEM140 gene and conﬁrmed the results using
immunoﬂuorescence with an antibody speciﬁc for TMEM140 in
cells. The results showed that TMEM140 was located in the
cytoplasm of Vero cells, with low expression and a diffuse or
punctuate cytoplasmic staining pattern (Fig. 1c). After transfection
of cells with the EGFP–UL31 and Flag-TMEM140 plasmid, soluble
TMEM140 was recruited by the expressed UL31 (EGFP–UL31) in
the cytoplasm and transferred to the nucleus with it. The dis-
tinctive co-localization of both molecules was observed at the
nuclear membrane and near the nucleoplasm (Fig. 1d). This co-
localization was conﬁrmed in Vero cells infected with HSV-1
(MOI¼0.1) (Fig. 1e). Together, these results suggest that UL31
interacts with TMEM140 in HSV-1 infected cells.
TMEM140 inhibits viral proliferation
The identiﬁed interaction between TMEM140 and UL31 and the
co-localization of the two molecules suggest that TMEM140 has an
essential function in viral infection. To study the effects of TMEM140
on HSV-1 infection, we ﬁrst determined the efﬁcacy of HSV-1
replication and proliferation when the normal expression level of
TMEM140 was altered. To ensure the accuracy of this experiment, a
MTT assay of the Vero cells transfected with the pcDNA3-TMEM140
expression vector and a siRNA speciﬁcally for the TMEM140 gene
was performed but did not affect cell viability (Fig. S1). Then, the
up-regulation and down-regulation of TMEM140 expression in Vero
cells were conﬁrmed using qRT-PCR and western blot assays
(Figs. 2a and b, right panel). Compared with the titers in the control
infection group, the average virus titers of up-regulation group were
reduced at 24–48 hpi (Fig. 2a), indicating that the transient over-
expression of TMEM140 inhibits viral proliferation. Moreover, when
TMEM140 expression was down-regulated in cells using RNAi
(Fig. 2b), virus proliferation was greater than that of the normal
control group at 24 and 36 hpi. (Fig. 2b). In the subsequent
experiment, re-introduction of the TMEM140 gene into TMEM140
gene knockdown cells overcame the siRNA interference effect on
viral replication (Fig. 2c). These results suggest that TMEM140 has a
potential inhibitory function in viral proliferation during viral
infection.
TMEM140 reduces the rate of HSV-1 nucleocapsid egress
Based on the interaction between TMEM140 and UL31 and the
essential function of the UL31 protein in nucleocapsid egress,
it was rational to hypothesize that TMEM140 may block the viral
nucleocapsid egress process and subsequently lead to a reduction
in the viral proliferation rate in cells via its potential interaction
with UL31. Therefore, viral nucleocapsid egress during transient
over-expression of TMEM140 in HSV-1-infected cells was observed
and quantiﬁed for 50 visible cells using transmission electron
microscopy. The results showed the clear presence of a large
number of viral nucleocapsids in the nuclei of infected cells in
which TMEM140 was transiently over-expressed (Fig. 3a). In
contrast, in the HSV-1-infected control group, fewer viral nucleo-
capsids were observed in the nucleus, and the majority of
nucleocapsids were released into the cytoplasm (Fig. 3a). Statis-
tical analysis showed that approximately 80% of the virions in
transiently over-expressing TMEM140 cells were viral nucleocap-
sids in the infected cell nucleus, compared with 30% for the
infected control cells, which meant that only 20% of the virions
in the transiently over-expressing TMEM140 cells were released
into the cytoplasm, compared with 70% for the infected control
cells (Fig. 3b). Therefore, it can be concluded that TMEM140 most
likely plays a major role in reducing the rate of viral nucleocapsid
egress from the nucleus, subsequently resulting in a reduction in
viral proliferation during HSV-1 infection.
TMEM140 blocks the formation of a functional UL31–UL34 complex
It has been reported that the egress of the HSV-1 nucleocapsid
is selectively regulated by the virally encoded proteins UL31 and
UL34, which interact and bind with each other to form a functional
protein complex that co-localizes to the nuclear rim and directly
aids in nucleocapsid egress from the nucleus (Reynolds et al.,
2001; Reynolds et al., 2002; Fuchs et al., 2002; Simpson-Holley et
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Fig. 1. Interaction between UL31 and TMEM140. (a) Yeast two-hybrid analysis of the physical interaction between UL31 and TMEM140. The yeast strain AH109 is
transformed with the indicated plasmid pairs: pGBKT7 and pGAD-140, pGBK–UL31 and pGADT7, pGAD-140 and pGBK–UL31, pGBK–UL31 and pGAD–UL34, pGBK–UL31 and
pGAD–LAMP3 or pGBK–UL31 and pGAD-176 or the negative control (pGAD-T and pGBK-Lam) or positive control (pGAD-T and pGBK-p53). The activity of β-galactosidase is
measured. The data represent the β-galactosidase activity values relative to those of the negative control from three independent experiments. (b) Co-immunoprecipitation
analysis of the interaction between UL31 and TMEM140. Vero cells are co-transfected with pcDNA–UL31 and pcDNA-140 or infected with HSV-1 (MOI¼0.1) for 36–40 h. In
each case, the cell lysates were ﬁrstly immunoprecipitated using mouse anti-UL31 or rabbit anti-TMEM140 (mouse or rabbit IgG as a control) antibody and immunoblotted
using a polyclonal TMEM140, UL31 or UL34 antibody. (c) Fluorescence detection of TMEM140 in Vero cells. Vero cells are transfected with pEGFP-140 or pEGFP–N2, as a
control, for 48 h, and samples are collected for ﬂuorescence microscopy (upper). Vero cells were ﬁxed and processed for immunoﬂuorescence using the anti-TMEM140
polyclonal antibody (lower). (d, e) The co-localization of UL31 and TMEM140. Vero cells are transfected with pEGFP–UL31 and pFlag-140 for 48 h, and the cells are ﬁxed and
processed for immunoﬂuorescence with the anti-Flag monoclonal antibody (d). Vero cells are infected with HSV-1 at a MOI of 0.1, and 20 h post-infection, the cells are ﬁxed
and processed for immunoﬂuorescence with the polyclonal anti-UL31 and anti-TMEM140 antibodies (e). Fluorescence image resolution, 20 μm.
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Fig. 2. TMEM140 represses the proliferation of HSV-1. (a) Vero cells in a 6-well plate are transfected with 3 μg of pcDNA-140 or the control pcDNA3 plasmid for 20 h and then infected
with HSV-1 (MOI¼0.1). At the indicated times post-infection, samples of infected cells are collected to measure the virus titer using a PFU assay (left). The expression of TMEM140 in
the Vero cells is determined using quantitative RT-PCR and immunoblotting (right). (b) Vero cells are transfected with TMEM140 si-140 siRNA or the scrambled interfering RNA as a
negative control at a concentration of 150 nM, and the inhibition of TMEM140 expression was quantiﬁed using quantitative RT-PCR and immunoblotting (right). At 24 h post-
transfection, the cells are infected with HSV-1 (MOI¼0.1), and at the indicated times post-infection, samples of infected cells are collected to measure the virus titer using a PFU assay
(left). (c) Vero cells are transfected with 150 nM TMEM140 siRNA for 12 h (scrambled interfering RNA as a negative control) and then transfected with 2 μg TMEM140 expression
plasmid pcDNA-140 (pcDNA3 plasmid as a negative control) as indicated. At 24 h post-transfection, the cells are infected with HSV-1 (MOI¼0.1), and at the indicated times post-
infection, samples of infected cells are collected to measure the virus titer using a PFU assay (left). The TMEM140 expression level of each group is quantiﬁed using quantitative RT-PCR
and immunoblotting (right). Error bars represent the standard deviation from triplicate samples. *Po0.05 by Student's t-test.
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al., 2004). The interaction between TMEM140 and UL31 might
interfere with the formation of the UL31–UL34 complex that is
required for the viral nucleocapsid egress and maturation of virus
particles, possibly resulting in a reduction in viral proliferation. To
explore the role of this process, immunoprecipitation was used to
observe the interaction between UL31 and UL34 in HSV-1-infected
cells in which TMEM140 was transiently over-expressed. As
indicated by the immunoprecipitation assay with an antibody
against UL31 and the following immunoblotting with an antibody
against UL34, the binding between UL31 and UL34 in HSV-1-
infected cells was reduced upon the transient over-expression
of TMEM140 (Fig. 4a). The immunoﬂuorescence assay using
antibodies against UL31, UL34 and TMEM140 indicated that the
interaction between UL31 and TMEM140 interfered with the
co-localization of UL31 and UL34 to the nuclear rim in cells
transfected with the TMEM140 gene and infected with HSV-1, as
shown by comparison with the co-localization of UL31 and UL34 in
infected control cells (Fig. 4b). The observation for the subsequent
immunoﬂuorescence assay and Western blotting using an anti-
body against the viral capsid structural protein VP5 showed fewer
viral nucleocapsids released into the cytoplasm of cells over-
expressing TMEM140 than that of the infection control (Fig. 4c).
This ﬁnding suggested that TMEM140 functioned by interfering
with release of the viral nucleocapsid from the nucleus into the
cytoplasm through interacting with UL31. In addition, the release
of nucleocapsids from the nucleus into the cytoplasm was reduced
in cells in which UL31 was down-regulated by a speciﬁc UL31-
interfering RNA (Fig. 4c, Fig. S2). This observation was further
Fig. 3. TMEM140 blocks the nucleocapsid egress of HSV-1. Vero cells transfected with pcDNA-140 or the control pcDNA3 plasmid for 30 h are infected at a MOI of 5 with
HSV-1 and incubated at 37 1C. At 17 h post-infection, samples of infected cells were harvested and ﬁxed, and the egress of viral nucleocapsid was assessed using transmission
electron microscopy (Hitachi H7650). Virions released into the cytoplasm are indicated by black arrows, and viral nucleocapsids in the nucleus are indicated by white arrows
(a). (b) Calculation of the virions per HSV-1-infected cells. The number of viral nucleocapsids as well as cytoplasmic capsids from 50 HSV-1 infected cells are calculated
relative to the total virions of the whole cells. Error bars represent the standard deviation from triplicate experiments. The expression levels of the TMEM140 and β-actin
(control) proteins are conﬁrmed using western blotting. *Po0.05 by Student's t-test (NM, nuclear membrane).
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supportive for the above suggestion. All of results here lead to a
conclusion that the interaction between TMEM140 and UL31
interferes with the formation of the UL31–UL34 complex and
might impact viral proliferation.
TMEM140 binds to UL31 via the CR1 domain
We lastly identiﬁed the domain of UL31 that interacts with
TMEM140. Because previous studies have indicated that the
critical binding site between the UL31 and UL34 proteins is the
ﬁrst conserved region (CR1) of UL31 (Lotzerich et al., 2006; Schnee
et al., 2006), an expression vector, pCMV-HA-31CR1, encoding the
CR1 sequence was constructed and co-transfected with the
TMEM140 expression vector into cells. The immunoprecipitation
results indicated a clear interaction between the TMEM140 and
UL31 CR1 proteins (Fig. 5). The site-directed mutation of six
conserved amino acids in the CR1 region showed that the critical
binding site in CR1 that interacts with TMEM140 includes the 94th
residue, which is a leucine, the mutation of which inhibited the
interaction between TMEM140 and UL31 (Fig. 5). These results
suggest that TMEM140 interacts with UL31 via a critical binding
site that is located in the UL31 CR1 region, which is the same
binding site as that for the interaction with UL34. This result
further supports our primary hypothesis that TMEM140 inhibits
HSV-1 proliferation via blocking the formation of the functional
UL31–UL34 complex in cells.
Discussion
Previous studies have demonstrated that the replication of
HSV-1, which has a complicated proliferation mechanism, involves
interactions between multiple virus-encoded molecules and various
cellular molecules. Importantly, the interaction between host and
virus molecules alters the cellular environment and subsequently
leads to the ﬁnal pathogenic process (Roizman and Taddeo, 2007).
Fig. 4. TMEM140 blocks the interaction between UL31 and UL34 and impedes viral nucleocapsid egress. (a) Interaction between UL31 and UL34 when the expression of
TMEM140 is up-regulated. Vero cells in 10-cm dishes were transfected with 6 μg of pcDNA-140 or the control plasmid, pcDNA3, for 30 h and then infected with HSV-1
(MOI¼0.1). At 24 h post-infection, equal amounts of whole-cell lysates are immunoblotted with polyclonal TMEM140 antibodies (upper panel) or immunoprecipitated with
the mouse anti-UL31 polyclonal antibody or mouse IgG, as a control, and then immunoblotted with the UL34 polyclonal antibody (lower panel). (b) The co-localization of
UL31 and UL34 when the expression of TMEM140 was upregulated. Vero cells in 3.5-cm dishes are transfected with 2 μg of pFlag-140 or the control plasmid, pFlag, for 30 h
and then infected with HSV-1 (MOI¼0.1). At 20 h post-infection, the cells are ﬁxed and processed for immunoﬂuorescence using the polyclonal anti-UL31, anti-UL34 and
anti-TMEM140 antibodies. The ﬂuorescent secondary antibodies included FITC-labeled anti-mouse IgG (green), TRITC-labeled anti-mouse IgG (red) and Alexa Fluor 555-
labeled anti-mouse IgG (blue). (c) Fluorescence and western blot detection of the inhibition of viral nucleocapsid egress by TMEM140. Vero cells are transfected with 100 nM
UL31 si-UL31 siRNA (or the scrambled interfering RNA si-negative as a control) or 3 μg of pFlag-140 plasmid for 30 h and then infected with HSV-1 (MOI¼0.1). At 18 h post-
infection, the cells are ﬁxed and processed for immunoﬂuorescence using the anti-VP5, anti-Flag and anti-UL31 antibodies. The ﬂuorescent secondary antibodies included
FITC-labeled anti-mouse IgG (green) and TRITC-labeled anti-mouse IgG (red). Moreover, the cell lysates of whole cells or cytoplasm are collected, and equal amounts of the
protein supernatants are subjected to western blotting using mouse anti-VP5 and anti-β-actin (control) monoclonal antibodies. The histogram represents the mean7SD of
the densitometric scans for the protein bands from three experiments that are normalized against β-actin and expressed as a percentage of the control group. Fluorescence
image resolution, 20 μm.
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Previous experiments have revealed that the process from nucleo-
capsid formation to assembly of the ﬁnal mature virion is a typical
biological event that depends on the interaction between virus-
associated molecules and cellular components at every step
(Mettenleiter, 2002; Johnson and Baines, 2011). It is presumed that
the process by which the HSV-1 nucleocapsid in the nucleus passes
through the double inner nuclear membrane and buds into the
cytoplasm is directly initiated by the formation of the nuclear egress
complex (NEC), the majority of which consists of the virus-encoded
proteins UL31 and UL34 (Mettenleiter, 2002; Mettenleiter et al.,
2013). The interaction between these two molecules is likely
followed by the recruitment of various components including
cellular protein kinase C and the viral molecules US3 and UL13, as
well as the cellular protein nucleolin and the virus-encoded
proteins UL12 and UL47, to alter the nuclear membrane structure
through phosphorylation of the nuclear lamina network (Johnson
and Baines, 2011; Kato et al., 2006; Reynolds et al., 2004; Simpson-
Holley et al., 2005; Mou et al., 2009; Leach and Roller, 2010; Sagou
et al., 2010; Liu et al., 2014). Thus, the interaction between UL31 and
UL34 likely plays an essential role in the formation of progeny
virions. The TMEM140 molecule that was identiﬁed in the current
study as an interacting partner of UL31 was not recruited to
facilitate mature virion assembly, but affected viral nucleocapsid
egress and proliferation through impeding the UL31–UL34 interac-
tion and, most likely, NEC formation. The results provide substantial
evidence indicating that NEC formation, especially the UL31–UL34
interaction, plays a vital role in HSV-1 nucleocapsid egress. Thus,
the inhibition of this process will lead to inhibition of the entire
infectious process, at least to some extent, following a decline in the
number of mature progeny virions.
Based on the MOI (0.1) that was used in this study, we
identiﬁed the presence of an interaction between TMEM140 and
UL31 during the process of viral nucleocapsid egress and mature
virion assembly at 18 h – 36 hpi. This time is reasonable because it
covers two passages of virus proliferation in cell. Importantly, this
interaction was conﬁrmed using immunoprecipitation and cellular
ﬂuorescence co-localization assays, and no impact of TMEM140 on
the transcription of the viral genome was found (Fig. S3). It is
proposed that TMEM140 binds to UL31 in the CR1 structural
domain, which is also the domain of UL31 that is bound by
UL34, suggesting that TMEM140 affects UL31–UL34 binding in a
steric manner. As shown using the immunoprecipitation and
cellular ﬂuorescence co-localization assays with HSV-1-infected
cells transiently over-expressing TMEM140; TMEM140-UL31
reduced the efﬁciency of UL31–UL34 binding. This result
contributes to our understanding of the reduction in HSV-1
proliferation in cells transiently over-expressing TMEM140 com-
pared with that in normal control cells. The electron microscopy
observations and the immunoﬂuorescence analysis of the VP5
structural protein that were performed in HSV-1-infected cells
revealed that over-expression of TMEM140 simply resulted in a
decrease in the HSV-1 nucleocapsid egress efﬁciency. This result
indicates that the viral proliferation efﬁciency could be affected by
TMEM140.
The potential mechanism by which the HSV-1 proliferation
efﬁciency was reduced was addressed in our current study by the
identiﬁcation of the ability of TMEM140 to impact the efﬁciency
of HSV-1 nucleocapsid egress via binding to the virus-encoded
protein UL31; however, the details of how this molecule affects
HSV-1 nucleocapsid egress and reduces viral proliferation via the
entire NEC complex must be further investigated. HSV-1 nucleo-
capsid egress via NEC formation is believed to be an important
step in viral proliferation, and the UL31 and UL34 proteins have
been found to play important roles in viral gene replication and
proliferation by recruiting glycoproteins D and M to increase
efﬁcacy (Chang et al., 1997; Wills et al., 2009; Roberts and
Baines, 2011). Therefore, inhibition of the UL31–UL34 interaction
using a mimic molecule, such as TMEM140 or a chemical com-
pound may be a potential strategy to control HSV proliferation
in cells.
Experimental procedures
Cell lines, viruses, plasmids and reagents
African monkey kidney cells (Vero) were cultured in DMEM
containing 10% calf serum at 37 1C. HSV-1 virus (F strain), which
was preserved by our laboratory, was grown in a monolayer of
Vero cells.
The eukaryotic expression plasmids pcDNA-UL31, pcDNA-140,
pGAD-140, pGBK-UL31, pEGFP-UL31, pEGFP-140, pFlag-140 and
pGAD-UL34 were constructed by inserting the HSV-1 UL31, UL34
or cellular TMEM140 gene sequences into the pcDNA3 (Invitro-
gen), pGBKT7, pGADT7, pEGFP-N2 (Clontech) and p3XFLAG-CMV
(Sigma-Aldrich) vectors. The UL31 CR1 region, 151–390 bp, was
inserted into the eukaryotic expression vector pCMV-HA (Clon-
tech) to construct the pCMV-HA-31CR1 plasmid. The pCMV-HA-
31CR1 mutation plasmids, in which the leucine (L) at position 94
of CR1 was mutated to glutamine (Q), the proline (P) at position 95
was mutated to histidine (H), the cysteine (C) at position 106 was
mutated to phenylalanine (F), the glycine (G) at position 113 was
Fig. 5. Interaction between UL31 CR1 and TMEM140. Diagram of the herpes UL31 ﬁrst conserved region (CR1) and the six site-directed amino acid mutations (left). Vero cells
in 10-cm dishes are transfected with the pCMV-HA-31CR1 plasmid, which contains the HSV-1 UL31 CR1 coding region, or the pCMV-HA-31CR1m plasmids, in which the
UL31 CR1 contained mutations at amino acids 94, 95, 106, 113, 122 and 125, as indicated. At 48 h post-transfection, the cells are immunoprecipitated using a mouse anti-HA
polyclonal antibody or mouse IgG as a control and immunoblotted using the TMEM140 polyclonal antibody (right).
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mutated to aspartic acid (D), the cysteine (C) at position 122 was
mutated to serine (S), and cysteine (C) at position 125 was
mutated to phenylalanine (F) (Fig. 5), were constructed using a
Site-directed Gene Mutagenesis Kit (Beyotime). The oligonucleo-
tide sequences for the ampliﬁcation of the above-mentioned genes
are shown in Table S2. All recombinant plasmids were analyzed
and conﬁrmed using enzyme digestion and sequencing. The
plasmids pGBKT7-Lam, pGBKT7-p53 and pGADT7-T from Clontech
were stored in our laboratory.
A rabbit anti-TMEM140 polyclonal antibody (HPA016871) was
purchased from Sigma-Aldrich (USA). The mouse anti-HA and anti-
Flag monoclonal antibodies (M20003 and M20008) were purchased
from Abmart (Shanghai, China). The mouse UL31 and UL34 antisera
were produced by our laboratory, and their speciﬁcities were
identiﬁed before use in experiments (Fig. S4). The rabbit anti-
GAPDH monoclonal antibody (AG019) and mouse anti-β-actin
monoclonal antibody (AA128) were purchased from Beyotime
Biotechnology (Wuhan China). The mouse anti-VP5 monoclonal
antibody (6F10) was purchased from Santa Cruz Biotechnology.
The peroxidase-conjugated goat anti-rabbit and goat anti-mouse
antibodies were purchased from Dingguo Biotechnology (Beijing,
China). The FITC-labeled goat anti-mouse IgG (HþL) and Alexa
Fluor 555-labeled donkey anti-mouse IgG (HþL) were purchased
from Beyotime Biotechnology. The TRITC-labeled goat anti-mouse
IgG was purchased from Dingguo Biotechnology (Beijing, China).
The Nuclear and Cytoplasmic Protein Extraction Kit (P0027) was
purchased from Beyotime Biotechnology.
Yeast two-hybrid screen and β-galactosidase assay
A yeast two-hybrid screen was performed using the MATCH-
MAKER GAL4 two-hybrid system 3 (Clontech, USA) according to
the manufacturer's protocols (Zhang et al., 2011). Brieﬂy, to test
the potential interaction between UL31 and TMEM140, the yeast
strains AH109 or Y187 were transformed with pGAD–TMEM140
and pGBK–UL31 and plated onto SD/-Leu/-Trp (DDO) or SD/-Ade/-
His/-Leu/-Trp medium (QDO). Yeast transformed with pGBKT7
plus pGAD–TMEM140 or pGBK–UL31 plus pGADT7 were used as
self-activation controls. Yeast transformed with pGBKT7-P53 plus
pGADT7-T or pGBKT7-lam plus pGADT7-T were used as positive
and negative controls, respectively. The plates were incubated at
30 1C until the appearance of colonies between 3 and 7 days. Then,
Y187 colonies growing on the DDO agar plates were picked and
subjected to β-galactosidase activity analysis following the manu-
facturer's instructions. The data represent the β-galactosidase
activity values relative to those of the negative control from three
independent experiments.
Fluorescence detection
Vero cells transfected with the chimeric EGFP plasmids (Lipo-
fectamine 2000, Invitrogen) and/or infected with HSV-1 were
grown for 24–48 h and subsequently treated with 4% polyformal-
dehyde and 0.2% Triton X-100 for 10 min to facilitate observation
using a ﬂuorescence microscope. Then, the transfected cells were
incubated with a mouse anti-UL31 antibody (1:400), anti-UL34
antibody (1:600), anti-TMEM140 antibody (1:50), anti-VP5 anti-
body (1:500), anti-Flag antibody (1:500) or anti-HA antibody
(1:500) for 2 h and further incubated with a FITC-, Alexa Fluor
555-, or TRITC-conjugated goat anti-mouse antibody (1:250) for
1 h. The slides were ﬁnally examined using a Nikon E600 ﬂuores-
cence microscope.
Cell viability assay
A total of 2104 Vero cells were plated onto 96-well plates
for 16 h. Each well of cells was then transfected with different
plasmids or siRNA. At different post-transfection times (12 h, 24 h,
36 h, 48 h and 60 h), the culture medium was removed and
replaced with culture medium containing 20 μl of sterile MTT
dye (5 mg/ml). After incubation at 37 1C for 4 h, the MTT solution
was removed, and 150 μl dimethyl sulfoxide (DMSO) was added to
each well followed by measuring the absorbance at 570 nm on an
enzyme immunoassay analyzer (Bio-Rad, USA).
Quantitative RT-PCR
Total RNA was extracted from the transfected Vero cells using
TRIzol reagent (Invitrogen) and reverse-transcribed into cDNA
using the supermoIII RT kit (Bioteke, Beijing). Real-time PCR
analysis of the TMEM140, UL31, ICP0, TK, gC and control β-actin
mRNAs was performed using the SYBR Premix Ex Tag II (Takara)
(Table S3). The TMEM140 and UL31 levels were normalized to the
β-actin RNA level, and the expression levels were calculated as
2△△Ct. All experiments were repeated three times, and the mean
value was calculated for statistical analysis.
Western blot analysis
The proteins from cell lysates were quantitated, and equal
amounts of supernatant protein were subjected to 10% SDS-PAGE.
The proteins were transferred to a PVDF membrane, which
was then blocked with 5% BSA-TTBS (BSA, 5%; Tris–HCl, 100 mM,
pH 7.5; NaCl, 0.9%; Tween-20, 0.2%). The membranes were subse-
quently treated with a speciﬁc primary antibody and a goat anti-
mouse or anti-rabbit IgG-HRP secondary antibody. Enhanced
chemiluminescence (ECL) detection of antigen–antibody com-
plexes using Immobilon Western HRP Substrates (Millipore) was
performed according to the standard protocol (Guo et al., 2012).
Bands were analyzed using densitometry and the ChemiDoc EQ
(Bio-Rad, USA) system. The band intensities were normalized
against β-actin and compared with that of the control group, and
the relative intensity ratios were calculated. Western blot analyses
of the proteins of interest were examined in three separate
experiments.
Immunoprecipitation
Vero cells were cultured in 10-cm cell culture plates, and the next
day, the cells were co-transfected with the indicated plasmids
(Lipofectamine 2000, Invitrogen) or infected with HSV-1 (MOI¼0.5).
The cells were washed with PBS 36–48 h post-transfection or post-
infection and lysed for 30 min in ice-cold RIPA lysis buffer (NaCl,
150 mmol/L; NP-40, 1%; sodium deoxycholate, 0.5%; SDS, 0.1%; Tris–
HCl, 50 mM, pH 7.5). The cell lysate was centrifuged at 14,000g for
10 min, and the supernatant was precleared by incubation with
protein AþG agarose beads (Beyotime Biotechnology) for 1 h at 4 1C.
An equal aliquot of the cell lysates was reserved as an input sample,
and the remaining lysates were incubated with anti-UL31 or anti-HA
antibodies under standard immunoprecipitation conditions and
incubated at 4 1C for 3 h with gentle agitation. Normal mouse IgGs
were used as controls. Protein A-agarose beads were added to the
protein-antibody mixture and incubated overnight at 4 1C with
rotation. The beads were collected using centrifugation, washed
three times with RIPA buffer and then subjected to sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
Viral titration
Vero cells were co-transfected with the indicated plasmids
(pcDNA3 as a control) for 20 h (Lipofectamine 2000, Invitrogen)
and then infected with HSV-1 at a MOI of 0.1. Then, 12–48 h post-
infection, samples of infected cells were collected to measure the
virus titer using a PFU assay. Brieﬂy, viral stocks were serially diluted
10 times, and the diluted stocks were added to six-well plates that
were coated with Vero cells. Subsequently, pre-warmed 1 DMEM
with 1% agar was added to the cell surface, and the plates were
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incubated at 37 1C for 4 to 5 days. Before the quantiﬁcation of plaque
formation, 4% paraformaldehyde and 0.5% crystal violet were added
to each well to ﬁx and dye the cells, respectively.
RNA interference (RNAi) for TMEM140
The siRNA duplexes si-140 (targeting TMEM140) and si-UL31
(targeting UL31) and the scrambled interfering RNA, si-negative,
which was used as the negative control, were chemically synthe-
sized using the 2'OME modiﬁcation by GenePharma (Shanghai,
China) and RiboBio (Guangzhou, China). (Table S4). All siRNAs
were stored in 0.1% diethylpyrocarbonate-treated water at 80 1C.
Before the experiment, the transfection efﬁciency of the siRNAwas
tested using ﬂuorescence-labeled siRNA. The result showed a
transfection efﬁciency of siRNA that was higher than 70% (Fig.
S5). Based upon this identiﬁed transfection efﬁciency, Vero cells
were seeded into the wells of 6-well plates. On the day after
seeding, the cells were transfected with si-140, si-UL31 or si-
negative at a ﬁnal concentration of 100–150 nM using the Lipo-
fectamine 2000 transfection reagent (Invitrogen) according to the
manufacturer's instructions. At 40 h after transfection, the trans-
fected cells were harvested, and total cellular protein extracts were
prepared for western blot analysis.
Electron microscopy
HSV-1-infected Vero cells were ﬁxed with 2.5% glutaraldehyde
prepared in 0.1 M cacodylate buffer (pH 7.3) and 1% osmium
tetroxide, followed by washing with double-distilled water three
times. The sample was subjected to gradient dehydration with
50%, 70%, 95% and 100% ethanol prior to being embedded in epoxy
resin. Ultrathin sections were double-stained with uranyl acetate
and lead citrate for transmission electron microscopy observations
(Hitachi H7650, Japan).
Statistical analysis
The data that were obtained from all experiments are pre-
sented as the mean7standard deviation (SD), and Po0.05 was
considered to be statistically signiﬁcant using Student's t-test.
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